Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a biotechnology company that focuses on RNA-targeted medicines for serious diseases, and its news flow reflects this emphasis on clinical, regulatory and commercial milestones. Company updates frequently highlight progress in neurology and cardiometabolic programs, as well as developments in rare conditions where few or no disease-modifying treatments exist.
Recent Ionis news has featured pivotal clinical trial readouts, such as Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, showing large reductions in triglyceride levels and acute pancreatitis events with favorable safety and tolerability. The company has also reported positive pivotal data for zilganersen in Alexander disease, describing evidence of disease-modifying impact in this rare and often fatal neurological condition.
Regulatory and commercial milestones are another major theme. Ionis has announced FDA approval of TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome and DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema in adults and adolescents 12 years and older. News items also cover FDA Breakthrough Therapy designations for olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease, as well as European regulatory opinions and anticipated launches.
Partnered program updates appear regularly, including GSK’s Phase 3 B-Well 1 and B-Well 2 results for bepirovirsen in chronic hepatitis B, Novartis’ Lp(a) HORIZON study of pelacarsen in cardiovascular disease, and AstraZeneca collaborations on WAINUA and eplontersen. Investors can also find coverage of Ionis’ financing activities, such as convertible note offerings, and its participation in healthcare and investor conferences.
For followers of IONS stock, this news page provides a centralized view of Ionis’ clinical trial milestones, FDA and EMA interactions, product launches, collaboration updates and capital markets events, helping readers understand how the company’s RNA-targeted pipeline and marketed medicines are evolving over time.
Ionis (Nasdaq: IONS) said the FDA accepted the New Drug Application for zilganersen for Alexander disease and granted Priority Review with a PDUFA target date of September 22, 2026. The pivotal study showed a 33.3% least-square-mean gait-speed improvement (10MWT) at week 61 (p=0.0412) with favorable safety. Zilganersen previously received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations. New pivotal-study data will be presented at the 2026 AAN annual meeting.
Ionis (Nasdaq: IONS) announced board changes effective June 4, 2026: B. Lynne Parshall and Joseph Wender will retire at term end, and Peter N. Reikes will rejoin the board.
Parshall and Wender are long-tenured directors; Reikes returns with recent roles at ARPA-H and the FDA and extensive healthcare finance experience.
Ionis (Nasdaq: IONS) will present new data supporting DAWNZERA (donidalorsen) for hereditary angioedema (HAE) at the 2026 AAAAI Annual Meeting in Philadelphia. Presentations include new analyses from the Phase 3 OASIS-HAE and OASISplus studies and one-year adolescent results.
Ionis will present eight poster presentations on Feb 27 and Mar 1, 2026, covering switching benefit, adherence, safety and efficacy in adolescents, patient-reported outcomes, predictors of disease control, unmet needs, and severity assessment.
Ionis (Nasdaq: IONS) announced the FDA has accepted the sNDA for olezarsen in severe hypertriglyceridemia (sHTG) and granted Priority Review, with a PDUFA target action date of June 30, 2026. The filing is supported by Phase 3 CORE and CORE2 results.
In those studies, olezarsen showed up to a 72% placebo-adjusted triglyceride reduction, an 85% reduction in acute pancreatitis events, and nearly 90% of treated patients reached triglycerides <500 mg/dL; safety and tolerability were described as favorable.
Ionis (Nasdaq: IONS) reported 2025 total revenue of $944 million (up from $705M in 2024), driven by commercial launches and a $280 million sapablursen upfront. TRYNGOLZA first-year net sales were $108 million. Cash and short-term investments were $2.7 billion at year-end.
2026 guidance: $800–$825M revenue, non-GAAP operating loss $500–$550M, and cash ~$1.6B.
Ionis (Nasdaq: IONS) said management will appear at six investor conferences in late February and March 2026, offering fireside chats and webcasts.
Dates include Feb 26, Mar 2, Mar 9, Mar 11 and Mar 17, 2026, with live webcasts and replays available on the company's investor website and archived for a limited time.
Ionis (NASDAQ: IONS) changed the start time for its fourth quarter and full year 2025 financial results webcast to 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. The date of the call is unchanged and a replay will be available for a limited time at the company's investor events page.
Ionis (Nasdaq: IONS) will host a live webcast on Wednesday, February 25, 2026 at 11:30 a.m. Eastern Time to discuss fourth quarter and full year 2025 financial results and to highlight progress on key programs. A replay will be available for a limited time on the investor events page.
Ionis (Nasdaq: IONS) and Otsuka announced that the European Commission approved DAWNZERA (donidalorsen) for routine prevention of hereditary angioedema (HAE) in adults and adolescents 12+ in the EU.
Approval follows positive Phase 3 OASIS-HAE and OASISplus data, including a 94% overall mean monthly attack rate reduction at one year in the OASISplus open-label extension. DAWNZERA is self-administered by subcutaneous autoinjector every four or eight weeks. Ionis is eligible for a $15 million milestone payment and tiered royalties up to 30% on net sales; Otsuka holds exclusive rights in Europe and Asia Pacific.
Ionis (Nasdaq: IONS) reported 2025 momentum and set 2026 catalysts including two planned independent launches and multiple Phase 3 readouts. TRYNGOLZA (olezarsen) generated preliminary U.S. net product sales of $105M in 2025 and a U.S. sNDA for severe hypertriglyceridemia was submitted; peak annual TRYNGOLZA net sales guidance was raised to >$2 billion. Positive pivotal Phase 3 topline results were announced for bepirovirsen in chronic hepatitis B with planned global regulatory submissions in 2026. Ionis expects a total of five Phase 3 readouts and four NDA/sNDA submissions in 2026, plus launches for DAWNZERA, olezarsen (sHTG) and zilganersen (Alexander disease), and targets cash flow breakeven in 2028.